Patents by Inventor Ching-Tai Huang
Ching-Tai Huang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240174747Abstract: Regulatory T cells (Treg) limit autoimmunity but can also attenuate the magnitude of anti-pathogen and anti-tumor immunity. Understanding the mechanism of Treg function and therapeutic manipulation of Treg in vivo requires identification of Treg selective receptors. A comparative analysis of gene expression arrays from antigen specific CD4+ T cells differentiating to either an effector/memory or a regulatory phenotype revealed Treg selective expression of LAG-3 (CD223), a CD4-related molecule that binds MHC class II. LAG-3 expression on CD4+ T cells correlates with the cells' in vitro suppressor activity, and ectopic expression of LAG-3 on CD4 T cells confers suppressor activity on the T cells. Antibodies to LAG-3 inhibit suppression both in vitro and in vivo. LAG-3 marks regulatory T cell populations and contributes to their suppressor activity.Type: ApplicationFiled: June 6, 2023Publication date: May 30, 2024Inventors: Drew M. Pardoll, Ching-Tai Huang, Jonathan Powell, Charles G. Drake, Dario A. Vignali, Creg J. Workman
-
Publication number: 20210230275Abstract: Combinations of anti-cancer antibodies and inhibitory antibodies to CD223 overcome immune suppression in cancer patients. The inhibitory antibodies may be generated in an animal by injection of fragments of CD223. Antibodies may be monoclonal antibodies or single chain antibodies or humanized antibodies.Type: ApplicationFiled: January 22, 2021Publication date: July 29, 2021Inventors: Drew Pardoll, Ching-Tai Huang, Jonathan Powell, Charles G. Drake, Dario A. Vignali, Creg J. Workman
-
Patent number: 10934354Abstract: Combinations of anti-cancer antibodies and inhibitory antibodies to CD223 overcome immune suppression in cancer patients. The inhibitory antibodies may be generated in an animal by injection of fragments of CD223. Antibodies may be monoclonal antibodies or single chain antibodies or humanized antibodies.Type: GrantFiled: March 30, 2018Date of Patent: March 2, 2021Assignees: The Johns Hopkins University, St. Jude's Children's Research Hospital, Inc.Inventors: Drew M. Pardoll, Ching-Tai Huang, Jonathan Powell, Charles G. Drake, Dario A. Vignali, Creg J. Workman
-
Patent number: 10787513Abstract: Anti-CD223 antibodies overcome immune suppression in cancer patients. The anti-CD223 antibodies may be generated in an animal by injection of fragments of CD223. Antibodies may be monoclonal antibodies or single chain antibodies or humanized antibodies.Type: GrantFiled: December 18, 2015Date of Patent: September 29, 2020Assignees: The Johns Hopkins University, St. Jude's Children's Research Hospital, Inc.Inventors: Drew M. Pardoll, Ching-Tai Huang, Jonathan Powell, Charles Drake, Dario A. Vignali, Creg J. Workman
-
Publication number: 20190240327Abstract: We demonstrate herein that neuritin controls the homeostasis of regulatory T cells in an antigen dependent manner. Based on this discovery, we describe herein the application of neuritin as a therapeutic agent to manipulate antigen specific regulatory T cells in various disease settings is described. Thus manipulation of Treg cells and DCs through neuritin can be used to enhance immunotherapy of autoimmune diseases, cancer and infectious diseases, as well as enhance lymphocyte engraftment in settings of donor lymphocyte infusion, bone marrow transplant, as well as other types of transplants, and adoptive transfer.Type: ApplicationFiled: November 8, 2013Publication date: August 8, 2019Inventors: Hong Yu, Drew M. Pardoll, Xiaoyu Pan, Charles G. Drake, Jonathan D. Powell, Ching-Tai Huang, Joseph Barbi, Fan Pan
-
Publication number: 20180251550Abstract: Combinations of anti-cancer antibodies and inhibitory antibodies to CD223 overcome immune suppression in cancer patients. The inhibitory antibodies may be generated in an animal by injection of fragments of CD223. Antibodies may be monoclonal antibodies or single chain antibodies or humanized antibodies.Type: ApplicationFiled: March 30, 2018Publication date: September 6, 2018Inventors: Drew M. Pardoll, Ching-Tai Huang, Jonathan Powell, Charles G. Drake, Dario A. Vignali, Creg J. Workman
-
Publication number: 20160108121Abstract: Combinations of anti-cancer antibodies and inhibitory antibodies to CD223 overcome immune suppression in cancer patients. The inhibitory antibodies may be generated in an animal by injection of fragments of CD223. Antibodies may be monoclonal antibodies or single chain antibodies or humanized antibodies.Type: ApplicationFiled: December 18, 2015Publication date: April 21, 2016Applicants: The Johns Hopkins University, St. Jude's Children's Research Hospital Inc.Inventors: Drew M. Pardoll, Ching-Tai Huang, Jonathan Powell, Charles Drake, Dario A. Vignali, Creg J. Workman
-
Patent number: 9005629Abstract: Mammals with cancer are treated with an antibody which specifically binds to CD223 protein and inhibits negative T cell regulatory function of CD223. The mammal may be a human. The antibody may be a monoclonal antibody. The amount of the antibody administered may be sufficient to enhance an immune T cell response to the cancer.Type: GrantFiled: November 16, 2012Date of Patent: April 14, 2015Assignees: St. Jude Children's Research Hospital Inc., The Johns Hopkins UniversityInventors: Drew M Pardoll, Ching-Tai Huang, Jonathan Powell, Charles Drake, Dario A Vignali, Creg J Workman
-
Publication number: 20140186374Abstract: We demonstrate herein that neuritin controls the homeostasis of regulatory T cells in an antigen dependent manner. Based on this discovery, we describe herein the application of neuritin as a therapeutic agent to manipulate antigen specific regulatory T cells in various disease settings is described. Thus manipulation of Treg cells and DCs through neuritin can be used to enhance immunotherapy of autoimmune diseases, cancer and infectious diseases, as well as enhance lymphocyte engraftment in settings of donor lymphocyte infusion, bone marrow transplant, as well as other types of transplants, and adoptive transfer.Type: ApplicationFiled: November 8, 2013Publication date: July 3, 2014Applicant: THE JOHNS HOPKINS UNIVERSITYInventors: Hong Yu, Drew M. Pardoll, Xiaoyu Pan, Charles G. Drake, Jonathan D. Powell, Ching-Tai Huang
-
Publication number: 20140127226Abstract: Regulatory T cells (Treg) limit autoimmunity but can also attenuate the magnitude of anti-pathogen and anti-tumor immunity. Understanding the mechanism of Treg function and therapeutic manipulation of Treg in vivo requires identification of Treg selective receptors. A comparative analysis of gene expression arrays from antigen specific CD4+ T cells differentiating to either an effector/memory or a regulatory phenotype revealed Treg selective expression of LAG-3 (CD223), a CD4-related molecule that binds MHC class II. LAG-3 expression on CD4+ T cells correlates with the cells' in vitro suppressor activity, and ectopic expression of LAG-3 on CD4 T cells confers suppressor activity on the T cells. Antibodies to LAG-3 inhibit suppression both in vitro and in vivo. LAG-3 marks regulatory T cell populations and contributes to their suppressor activity.Type: ApplicationFiled: December 13, 2013Publication date: May 8, 2014Applicants: St. Jude's Children's Research Hospital Inc., The Johns Hopkins UniversityInventors: Drew M. PARDOLL, Ching-Tai HUANG, Jonathan POWELL, Charles DRAKE, Dario A. VIGNALI, Creg J. WORKMAN
-
Patent number: 8551481Abstract: Regulatory T cells (Treg) limit autoimmunity but can also attenuate the magnitude of anti-pathogen and anti-tumor immunity. Understanding the mechanism of Treg function and therapeutic manipulation of Treg in vivo requires identification of Treg selective receptors. A comparative analysis of gene expression arrays from antigen specific CD4+ T cells differentiating to either an effector/memory or a regulatory phenotype revealed Treg selective expression of LAG-3 (CD223), a CD4-related molecule that binds MHC class II. LAG-3 expression on CD4+ T cells correlates with the cells' in vitro suppressor activity, and ectopic expression of LAG-3 on CD4 T cells confers suppressor activity on the T cells. Antibodies to LAG-3 inhibit suppression both in vitro and in vivo. LAG-3 marks regulatory T cell populations and contributes to their suppressor activity.Type: GrantFiled: October 22, 2009Date of Patent: October 8, 2013Assignees: The Johns Hopkins University, St. Jude Children's Research Hospital, Inc.Inventors: Drew M Pardoll, Ching-Tai Huang, Jonathan Powell, Charles Drake, Dario A Vignali, Creg J Workman
-
Publication number: 20100196394Abstract: Combinations of anti-cancer vaccines and inhibitory antibodies to CD223 overcome immune suppression in cancer patients. The vaccines may be isolated antigens, groups of antigens, or whole tumor cells. The inhibitory antibodies may be generated in an animal by injection of fragments of CD223. Antibodies may be monoclonal antibodies or single chain antibodies or humanized antibodies.Type: ApplicationFiled: October 22, 2009Publication date: August 5, 2010Applicants: THE JOHNS HOPKINS UNIVERSITY, ST. JUDE CHILDREN'S RESEARCH HOSPITAL INC.Inventors: Drew M. Pardoll, Ching-Tai Huang, Dario A. Vignali, Creg J. Workman, Jonathan Powell, Charles C. Drake
-
Publication number: 20100040636Abstract: We demonstrate herein that neuritin controls the homeostasis of regulatory T cells in an antigen dependent manner. Based on this discovery, we describe herein the application of neuritin as a therapeutic agent to manipulate antigen specific regulatory T cells in various disease settings is described. Thus manipulation of Treg cells and DCs through neuritin can be used to enhance immunotherapy of autoimmune diseases, cancer and infectious diseases, as well as enhance lymphocyte engraftment in settings of donor lymphocyte infusion, bone marrow transplant, as well as other types of transplants, and adoptive transfer.Type: ApplicationFiled: September 11, 2006Publication date: February 18, 2010Applicant: The Johns Hopkins UniversityInventors: Hong Yu, Drew Pardoll, Xiaoya Pan, Charles George Drake, Jonathan D. Powell, Ching-Tai Huang
-
Publication number: 20060240024Abstract: Regulatory T cells (Treg) limit autoimmunity but can also attenuate the magnitude of anti-pathogen and anti-tumor immunity. Understanding the mechanism of Treg function and therapeutic manipulation of Treg in vivo requires identification of Treg selective receptors. A comparative analysis of gene expression arrays from antigen specific CD4+ T cells differentiating to either an effector/memory or a regulatory phenotype revealed Treg selective expression of LAG-3 (CD223), a CD4-related molecule that binds MHC class II. LAG-3 expression on CD4+ T cells correlates with the cells' in vitro suppressor activity, and ectopic expression of LAG-3 on CD4 T cells confers suppressor activity on the T cells. Antibodies to LAG-3 inhibit suppression both in vitro and in vivo. LAG-3 marks regulatory T cell populations and contributes to their suppressor activity.Type: ApplicationFiled: March 1, 2004Publication date: October 26, 2006Applicants: The Johns Hopkins University, St Jude Children's Research Hospital Inc.Inventors: Drew Pardoll, Ching-Tai Huang, Dario Vignali, Creg Workman, Jonathan Powell, Charles Drake